Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again

Phase 3positiveNegative

AI Analysis

Summary

Zealand Pharma's Phase 3 weight loss drug met primary endpoints but achieved only up to 9.8% weight loss, underperforming competitor products. The modest efficacy data disappointed investors, causing ZEAL shares to decline in premarket trading.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Met primary endpoints with up to 9.8% weight loss, but inferior to competitors

Importance:7/10

Sentiment:

-0.60

Phase 3 trialweight lossprimary endpoint metcompetitive disadvantagestock decline

Related Companies

$ZEAL

Read the original article

Published by BioSpace on October 1, 2026 2:32 PM

Read Original